Add-on PD-1 inhibitor with Peg-IFNα therapy favors functional cure of chronic hepatitis B patients
Quarterly sintilimab add-on therapy triples the short-term HBsAg clearance rate in interferon-refractory CHB without major additional toxicity. A week-12 ALT surge and elevated OAS1 may serve as early biomarkers of response, but confirmation in larger randomized trials is needed.
Authors
- Chenrui Liu (ORCID: https://orcid.org/0009-0003-3393-0394)
- Yaping Li
- Xi Zhang (ORCID: https://orcid.org/0000-0002-4638-3997)
- Ling He (ORCID: https://orcid.org/0000-0003-1666-6459)
- Fusheng Wang
- Shuangsuo Dang
- Guoe Gou
- J L Fu
- Dandan Feng
- Liu Yang
- Mei Li
Institutions
- Chinese PLA General Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Journal of Translational Internal Medicine
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1515/jtim-2026-0018
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00